NIMG-53. POST-SURGICAL, RESIDUAL ENHANCING TUMOR VOLUME IS PROGNOSTIC FOR OVERALL SURVIVAL IN NEWLY DIAGNOSED GLIOBLASTOMA: EVIDENCE FROM 1,458 PATIENTS POOLED FROM INTERNATIONAL TRIALS, SINGLE INSTITUTION DATABASES, AND MULTICENTER CONSORTIUMS

The prognostic significance of residual contrast enhancing tumor volume after initial surgery to predict OS in newly diagnosed GBM remains poorly understood and not controlled for in prospective clinical trials. In the current study we pooled imaging data in >1,400 newly diagnosed GBM patients from international multicenter clinical trials, single institution databases, and multicenter clinical trial consortiums identify relationships between clinical parameters, MGMT methylation status, treatment, and residual enhancing tumor volume on OS.